Therapeutic applications of gene editing in chronic liver diseases: an update

키워드

참고문헌 (61)

1. Hackl C, "Current developments in pediatric liver transplantation", World J Hepatol, 7, pp.1509~1520 (2015)
2. Blaese RM, "T lymphocyte-directed gene therapy for ADA-SCID : initial trial results after 4 years", Science, 270, pp.475~480 (1995)
3. Kumar SR, "Clinical development of gene therapy : results and lessons from recent successes", Mol Ther Methods Clin Dev, 3, pp.16034~ (2016)
4. Raper SE, "Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer", Mol Genet Metab, 80, pp.148~158 (2003)
5. Rees HA, "Base editing : precision chemistry on the genome and transcriptome of living cells", Nat Rev Genet, 19, pp.770~788 (2018)
6. Gaudelli NM, "Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage", Nature, 551, pp.464~471 (2017)
7. Anzalone AV, "Searchand-replace genome editing without double-strand breaks or donor DNA", Nature, 576, pp.149~157 (2019)
8. Anzalone AV, "Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors", Nat Biotechnol, 38, pp.824~844 (2020)
9. Miranda E, "A novel monoclonal antibody to characterize pathogenic polymers in liver disease associated with alpha1-antitrypsin deficiency", Hepatology, 52, pp.1078~1088 (2010)
11. Smith C, "Efficient and allele-specific genome editing of disease loci in human iPSCs", Mol Ther, 23, pp.570~577 (2015)
12. Carlson JA, "Accumulation of PiZ alpha 1-antitrypsin causes liver damage in transgenic mice", J Clin Invest, 83, pp.1183~1190 (1989)
13. Song CQ, "In vivo genome editing partially restores alpha1-antitrypsin in a murine model of AAT deficiency", Hum Gene Ther, 29, pp.853~860 (2018)
14. Bjursell M, "Therapeutic genome editing with CRISPR", Cas9 in a humanized mouse model ameliorates alpha1-antitrypsin deficiency phenotype, 2018, pp.29, 104~111
15. Shen S, "Amelioration of alpha-1 antitrypsin deficiency diseases with genome editing in transgenic mice", Hum Gene Ther, 29, pp.861~873 (2018)
16. Stephens CJ, "Targeted in vivo knock-in of human alpha-1-antitrypsin cDNA using adenoviral delivery of CRISPR", Cas9, 2018, pp.25, 139~156
17. Borel F, "Survival advantage of both human hepatocyte xenografts and genome-edited hepatocytes for treatment of alpha-1 antitrypsin deficiency", Mol Ther, 25, pp.2477~2489 (2017)
18. Bagnall RD, "Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A", Blood, 99, pp.168~174 (2002)
19. Park CY, "Functional correction of large factor VIII gene chromosomal inversions in hemophilia A patient-derived iPSCs using CRISPR-Cas9", Cell Stem Cell, 17, pp.213~220 (2015)
20. Park CY, "Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs", Proc Natl Acad Sci U S A, 111, pp.9253~9258 (2014)
21. Wu Y, "In situ genetic correction of F8 intron 22 inversion in hemophilia A patient-specific iPSCs", Sci Rep, 6, pp.18865~ (2016)
22. Park CY, "Universal correction of blood coagulation factor viii in patient-derived induced pluripotent stem cells using CRISPR", Cas9, 2019, pp.12, 1242~1249
23. 성진재, "Restoration of FVIII expression by targeted gene insertion in the FVIII locus in hemophilia A patient-derived iPSCs", Experimental and Molecular Medicine, 51, pp.1~9 (2019), 생화학분자생물학회[DOI]
24. Sharma R, "In vivo genome editing of the albumin locus as a platform for protein replacement therapy", Blood, 126, pp.1777~1784 (2015)
25. Conway A, "Non-viral delivery of zinc finger nuclease mRNA enables highly efficient in vivo genome editing of multiple therapeutic gene targets", Mol Ther, 27, pp.866~877 (2019)
26. Barzel A, "Promoterless gene targeting without nucleases ameliorates haemophilia B in mice", Nature, 517, pp.360~364 (2015)
27. Stephens CJ, "Long-term correction of hemophilia B using adenoviral delivery of CRISPR", Cas9, 2019, pp.298, 128~141
28. Anguela XM, "Robust ZFN-mediated genome editing in adult hemophilic mice", Blood, 122, pp.3283~3287 (2013)
29. Lyu C, "Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system", Stem Cell Res Ther, 9, pp.92~ (2018)
30. Blau N, "Phenylketonuria", Lancet, 376, pp.1417~1427 (2010)
31. Strisciuglio P, "New strategies for the treatment of phenylketonuria(PKU)", Metabolites, 4, pp.1007~1017 (2014)
32. Blau N, "Molecular genetics and diagnosis of phenylketonuria : state of the art", Expert Rev Mol Diagn, 14, pp.655~671 (2014)
33. Pan Y, "CRISPR RNAguided FokI nucleases repair a PAH variant in a phenylketonuria model", Sci Rep, 6, pp.35794~ (2016)
34. McDonald JD, "The use of N-ethyl-N-nitrosourea to produce mouse models for human phenylketonuria and hyperphenylalaninemia", Prog Clin Biol Res, 340C, pp.407~413 (1990)
35. Villiger L, "Treatment of a metabolic liver disease by in vivo genome base editing in adult mice", Nat Med, 24, pp.1519~1525 (2018)
36. Tanzi RE, "The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene", Nat Genet, 5, pp.344~350 (1993)
37. Sternlieb I, "Lysosomal defect of hepatic copper excretion in Wilson’s disease(hepatolenticular degeneration)", Gastroenterology, 64, pp.99~105 (1973)
38. Murillo O, "Long-term metabolic correction of Wilson’s disease in a murine model by gene therapy", J Hepatol, 64, pp.419~426 (2016)
39. Donovan K, "StatPearls" (2021), Treasure Island (FL)
40. Hodges PE, "The spfash mouse : a missense mutation in the ornithine transcarbamylase gene also causes aberrant mRNA splicing", Proc Natl Acad Sci U S A, 86, pp.4142~4146 (1989)
41. Yang Y, "A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice", Nat Biotechnol, 34, pp.334~338 (2016)
42. Lindstedt S, "Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase", Lancet, 340, pp.813~817 (1992)
43. Azuma H, "Robust expansion of human hepatocytes in Fah-", -, -, pp.Il2rg-, -mice[DOI]
44. Paulk NK, "Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo", Hepatology, 51, pp.1200~1208 (2010)
45. Yin H, "Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype", Nat Biotechnol, 32, pp.551~553 (2014)
46. Yao X, "CRISPR", Cas9-mediated precise targeted integration in vivo using a double cut donor with short homology arms, 2017, pp.20, 19~26
47. Shao Y, "Cas9-nickasemediated genome editing corrects hereditary tyrosinemia in rats", J Biol Chem, 293, pp.6883~6892 (2018)
48. Shin JH, "In vivo gene correction with targeted sequence substitution through microhomology-mediated end joining", Biochem Biophys Res Commun, 502, pp.116~122 (2018)
49. VanLith CJ, "Ex vivo hepatocyte reprograming promotes homology-directed DNA repair to correct metabolic disease in mice after transplantation", Hepatol Commun, 3, pp.558~573 (2019)
50. VanLith C, "Curative ex vivo hepatocyte-directed gene editing in a mouse model of hereditary tyrosinemia type 1", Hum Gene Ther, 29, pp.1315~1326 (2018)
51. Mangeot PE, "Genome editing in primary cells and in vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins", Nat Commun, 10, pp.45~ (2019)
52. Ibraheim R, "All-in-one adeno-associated virus delivery and genome editing by Neisseria meningitidis Cas9 in vivo", Genome Biol, 19, pp.137~ (2018)
53. Rossidis AC, "In utero CRISPR-mediated therapeutic editing of metabolic genes", Nat Med, 24, pp.1513~1518 (2018)
54. Diez-Fernandez C, "Mutations and common variants in the human arginase 1(ARG1)gene : Impact on patients, diagnostics, and protein structure considerations", Hum Mutat, 39, pp.1029~1050 (2018)
55. Sin YY, "Proof-of-concept gene editing for the murine model of inducible arginase-1 deficiency", Sci Rep, 7, pp.2585~ (2017)
56. Sin YY, "Transplantation of gene-edited hepatocyte-like cells modestly improves survival of arginase-1-deficient mice", Mol Ther Nucleic Acids, 10, pp.122~130 (2018)
57. Kim Y, "Adenine base editing and prime editing of chemically derived hepatic progenitors rescue genetic liver disease", Cell Stem Cell, 28, pp.1614~1624 (2021)
58. Kim Y, "Small molecule-mediated reprogramming of human hepatocytes into bipotent progenitor cells", J Hepatol, 70, pp.97~107 (2019)
59. Rothgangl T, "In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels", Nat Biotechnol, 39, pp.949~957 (2021)
60. Musunuru K, "In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates", Nature, 593, pp.429~434 (2021)
61. Gillmore JD, "CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis", N Engl J Med, 385, pp.493~502 (2021)

관련 논문AI추천